Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Kerr RS., Love S., Segelov E., Johnstone E., Falcon B., Hewett P., Weaver A., Church D., Scudder C., Pearson S., Julier P., Pezzella F., Tomlinson I., Domingo E., Kerr DJ.

DOI

10.1016/s1470-2045(16)30172-3

Type

Journal article

Journal

The Lancet Oncology

Publisher

Elsevier BV

Publication Date

11/2016

Volume

17

Pages

1543 - 1557

Permalink Original publication